Cargando…

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

BACKGROUND: Secondary hyperparathyroidism (SHPT) is a severe complication for dialysis patients. Vitamin D receptor activators (VDRAs) are used to treat SHPT, but the comparative efficacy and safety between paricalcitol and other vitamin D receptor activators for management of SHPT in dialysis patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Yifeng, Su, Peiling, Sun, Yifan, Zhang, Hongsheng, Zhao, Rong, Li, Liang, Meng, Lanfen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574209/ https://www.ncbi.nlm.nih.gov/pubmed/28841848 http://dx.doi.org/10.1186/s12882-017-0691-6

Ejemplares similares

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study
por: Xie, Shuqin, et al.
Publicado: (2022)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis
por: Franchi, Matteo, et al.
Publicado: (2023)

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
por: Hansen, Ditte, et al.
Publicado: (2009)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients
por: Zheng, Jing-Quan, et al.
Publicado: (2016)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient
por: Cozzolino, Mario, et al.
Publicado: (2008)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

Efficacy and safety of radiofrequency ablation versus parathyroidectomy for secondary hyperparathyroidism in dialysis patients: a single-center retrospective study
por: Ren, Mian, et al.
Publicado: (2022)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol
por: Mimura, Luiza Ayumi Nishiyama, et al.
Publicado: (2021)

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis
por: Liu, Yang, et al.
Publicado: (2019)

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease
por: Webb, Nicholas J. A., et al.
Publicado: (2017)

Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Koohpeyma, Farhad, et al.
Publicado: (2021)

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison
por: Zawierucha, Jacek, et al.
Publicado: (2019)

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020)

Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s
por: Ketteler, Markus, et al.
Publicado: (2022)

Risk factors for severe hypocalcemia after parathyroidectomy in dialysis patients with secondary hyperparathyroidism
por: Sun, Xiaoliang, et al.
Publicado: (2018)

Ectopic ossification in the cranial dura mater in dialysis patients with secondary hyperparathyroidism
por: Oyama, Yuko, et al.
Publicado: (2010)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency
por: Elbers, Laura P B, et al.
Publicado: (2018)

A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials
por: Geng, Xinghua, et al.
Publicado: (2020)

The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection
por: Duplancic, Darko, et al.
Publicado: (2013)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Efficacy and safety of radiofrequency ablation for primary and secondary hyperparathyroidism: a retrospective study
por: Qiu, Xinguang, et al.
Publicado: (2023)

Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol
por: Anis, Karim H., et al.
Publicado: (2020)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
por: Abbas, Fizza, et al.
Publicado: (2019)

Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism
por: Zhang, Yi, et al.
Publicado: (2019)

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bgev1ulqu35vtutcaton4907gs